Zymeworks: Citi Flags Major Upside Catalyst Ahead of August 25 FDA Decision

Citi places Zymeworks on 90-day upside watch with Buy rating and $37 target ahead of the Aug 25 FDA decision on zanidatamab for HER2+ GEA.